期刊文献+

口腔颌面部恶性肿瘤尿激酶及其受体的基因表达和临床意义 被引量:5

Gene expression and significance of urokinase type plasminogen activator and its receptor in oral and maxillofacial tumor tissue
下载PDF
导出
摘要 目的:探讨uPA及uPAR与口腔颌面部恶性肿瘤浸润、转移的关系。方法:应用cDNA-m RNA斑点杂交技术定量检测30 例口腔颌面部恶性肿瘤uPA和uPARm RNA表达水平。结果:癌组织uPA和uPARm RNA含量高于相应正常组织(P< 0.01),伴有淋巴结转移癌组织uPA 和uPAR高于无淋巴结转移者(P< 0.01,P< 0.05),uPA、uPAR表达水平与淋巴结转移关系密切(r= 0.41 P< 0.01,r= 0.31 P< 0.05),与T分期、分化程度及肿瘤类型无明显关系。结论:uPA 和uPAR是促进口腔颌面部恶性肿瘤转移的重要因素,其表达水平可作为肿瘤转移的参考指标。 Objective:To investigate the relationship between gene expression levels of urokinase type plasminogen activator (uPA) & its receptor (uPAR) and biological behavior of oral and maxillofacial malignancies.Methods:The mRNA contents of uPA and uPAR in samples were quantitatively detected by cDNA mRNA dot blot hybridization. Results:The malignent tumors had greatly higher mRNA contents of uPA and uPAR than those in their relevant surrounding tissues ( P <0 01). These mRNA contents in cancer tissues with lymphatic metastases were higher than those without lymphatic metastases ( P <0 01 and P <0 05); lymphatic metastases were mainly affected by these genes expression levels ( r =0 41 P <0 01, r =0 31 P <0 05). T classification, differential degradation or tumor kind wasn′t correlated with uPA or uPAR mRNA content. Conclusion:The overexpression of uPA and uPAR gene is an important factor in the metastases of promoting oral and maxillofacial malignent tumors. It may be used as a symbol of tumor metastasis to detect these mRNA contents.
出处 《军医进修学院学报》 CAS 1999年第4期270-272,共3页 Academic Journal of Pla Postgraduate Medical School
关键词 尿激酶型 纤溶酶原激活剂 受体 口腔颌面部肿瘤 urokinase type plasminogen activator receptor oral and maxillofacial tumor
  • 相关文献

参考文献1

二级参考文献1

  • 1J. E. Testa,J. P. Quigley. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior[J] 1990,CANCER AND METASTASIS REVIEW(4):353~367

共引文献1

同被引文献28

  • 1梁新华,冯戈,王大章,毛祖彝,冷卫东,何嘉.热休克对人舌癌Tca8113细胞尿激酶型纤溶酶原激活物受体表达的影响[J].实用口腔医学杂志,2004,20(6):727-729. 被引量:2
  • 2毛祖彝.头颈部恶性肿瘤的加温(热)治疗[A].邱蔚六.口腔颌面外科的理论和实践[C].北京:人民卫生出版社,1998.1525-1536.
  • 3[1]Glayman G, Wang S .W, Nicolson G.L, et al: Regulation of urokinase -type plasminogen activator expression in squamous-cell carcinoma of the oral cavity[J]. Int J Cancer,1993, 54:73~80
  • 4[3]Navarro AD, Lopez GM, Villaneva AO, et al. Urokinasetype plasminogen activator and plasminogen activator inhibitors(pai-1 and pai-2) in extracts of invasive cervical carcinoma and precursor lesions[J]. Eur J Cancer, 1998, 34:566 ~ 569
  • 5[5]Duffy MJ, Reilly. D, Osullivan. C,et al. Urokinaseplasminogen activator, a new and independent prognostic marker in breast cancer[J]. Cancer Res, 1990, 50: 6827~ 6829
  • 6[6]Borstnar S, Vrhovec I, Svetic B, et al. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients[J]. Clin Breast Cancer,2002, Jun, 3 (2): 138~146
  • 7[7]Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780breast cancer patients[J]. Cancer Res, 2000,60 (3): 636~ 643
  • 8[8]Yasuhiro I, Tsoutomu T, Tetsuro K, et al. Plasminogen activation system is active even in thyroid tumors: An immunohistochemical study[J]. Anticancer Research, 1996,16:81~90
  • 9[9]Plebani M, Herszenyi L, Carraro P, et al. Urokinase-type plasminogen activator receptor in gastric cancer :tissue expression and prognostic role[J]. Clin Exp Metastasis, 1997,15:418~425
  • 10[10]Nozaki S, Endo Y, Kawashir S, et al. Immunohistochemical localization of a urokinase -type plasminogen activator system in squamous cell carcinoma of the oral cavity:association with mode of invasion and lymph node metastasis[J]. Oral Oncol, 1998, 34:58~62

引证文献5

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部